Morshaeuser L, et al. - The purpose of this trial was to externally validate a molecular multi-marker panel included in a previously proposed prognostic nomogram for the speculation of postoperative disease-free survival. p53 exhibited a statistically marked impact on disease progression (DP), not on cancer-specific mortality (CSM) when applying the 10% expression cut-off as used in the original nomogram. Nevertheless, the prognostic value of all other examined markers included in the nomogram was yet to be confirmed. p53 independently exerted an influence on DP and CSM, while the PA was not significantly enhanced when an alternative cut-off of 20% was applied in multivariable models. The clinical importance of p53 remained to be determined. The utility of p53-expression and the Klatte nomogram was not recommended in routine clinical decision-making.